Results

1–10 of 77 results for ranibizumab

Safety and Efficacy of Switching to Biosimilar Ranibizumab in Eyes Initially Treated With Reference Ranibizumab for nAMD, DME, or RVO
Nikhil K Bommakanti, MD
Annual Meeting Talks
2024
Durability of Combination Therapy of Sozinibercept, an Anti-VEGF-C/D 'Trap' With Ranibizumab in nAMD or Aflibercept in DME
Nathan C. Steinle, MD
Annual Meeting Talks
2024
Subretinal Aflibercept vs Ranibizumab vs Bevacizumab in the Context of PPV: Pneumatic Displacement With Subretinal Air and tPA in Naïve Submacular Hemorrhage Due to nAMD
Matias Iglicki, MD
Annual Meeting Talks
2024
Baseline Factors Associated With 1-Year Outcomes in Phase III Comparison of SB11 (Approved Ranibizumab Biosimilar) With Reference Ranibizumab in nAMD
Neil M. Bressler, MD
Annual Meeting Talks
2022
End-of-Study Retinal Fluid and Vision Outcomes in the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab in Patients With nAMD
Aleksandra V. Rachitskaya, MD, FASRS
Annual Meeting Talks
2022
Key Surgical Pearls for the Prevention of Conjunctival Complications Following the Port Delivery System With Ranibizumab (PDS) Implant Insertion Procedure
On Demand Cases, Courses, and Papers
2022
Anterior Segment OCT for Evaluation of the Implantation Site of the Port Delivery System With Ranibizumab
On Demand Cases, Courses, and Papers
2022
The Impact of the COVID-19 Pandemic on Aflibercept and Ranibizumab Anti-VEGF Injections
Kapil Mishra, MD
On Demand Cases, Courses, and Papers
2021
Treatment Switch From Aflibercept to Ranibizumab Pre-filled Syringe in Canadian DME Patients in a Real-World Setting: The PRECISE Study
Michel R Giunta, MD
On Demand Cases, Courses, and Papers
2021
Analysis of Retinal Fluid and Vision Outcomes in the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS) in Patients With nAMD
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2021